Drugs.com Twitter


Class: Loop Diuretics
VA Class: CV702
CAS Number: 54-31-9
Brands: Lasix

  • Furosemide is a potent diuretic that given in excessive amounts may induce a profound diuresis with water and electrolyte depletion.133 e Careful medical supervision is required; dosage selection and titration should be adjusted to the individual patient’s needs.133 e (See Dosage and Administration.)


A sulfonamide, loop-type diuretic and antihypertensive agent.133 e

Uses for Furosemide


Management of edema associated with CHF, hepatic cirrhosis, and renal disease (e.g., nephrotic syndrome).133 e

Considered a diuretic of choice for most patients with CHF.131

IV management of acute pulmonary edema (in combination with oxygen and a cardiac glycoside).150


Management of hypertension (alone or in combination with other classes of antihypertensive agents).100 101 109 124 127 133 144

One of several preferred initial therapies in hypertensive patients with CHF or renal disease.100 101 109 124 127 144

Can be used as monotherapy for initial management of uncomplicated hypertension; however, thiazide diuretics are preferred by JNC 7.100 101 124 127 142 143 144

Furosemide Dosage and Administration



  • Careful etiologic diagnosis should precede the use of any diuretic.e

  • Hospitalization of the patient during initiation of therapy is advisable, especially for patients with hepatic cirrhosis and ascites or chronic renal failure.133 e

  • Most experts state that all patients with symptomatic CHF who have evidence for, or a prior history of, fluid retention generally should receive diuretic therapy in conjunction with moderate sodium restriction (≤3 g of sodium daily), an ACE inhibitor, and usually a β-blocker, with or without a cardiac glycoside.131

  • In prolonged diuretic therapy, intermittent use of the drug (e.g., on 2–4 consecutive days each week) may be advisable.e


  • Monitor BP carefully, especially during initial therapy.133

  • If added to regimen of a patient receiving another antihypertensive agent, reduce dosage of preexisting therapy by at least 50% initially to avoid severe hypotension; additional dosage adjustment may be required.133


Administer orally, IV, or IM.133 150

Oral Administration

Administer orally once (preferably in the morning)e or twice daily .133

For ease of administration and maximum dosage flexibility in children, consider use of oral solution preparation.151

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

IV administration may be used in emergency clinical circumstances when a rapid onset of diuresis is desired, or in patients unable to take oral medication or those with impaired GI absorption; replace with oral therapy as soon as possible.133 150 e

Consider the potential risks, when using large parenteral doses; monitor patient closely.105 107


For IV infusion, dilute in 5% dextrose, 0.9% sodium chloride, or lactated Ringer’s injection and adjust pH to >5.5.150 e

Whenever possible, use vials instead of ampuls to prepare large doses to prevent large quantities of glass particles from entering the solutions.e If ampuls must be used, consider filtering through a sterile membrane filter before use to remove any particles that may be present.e

Rate of Administration

For direct IV injection, administer slowly over a period of 1–2 minutes.150 e

If high-dose parenteral furosemide therapy is necessary, the manufacturer recommends that the drug be administered as a controlled infusion at a rate not exceeding 4 mg/minute in adults.150 e


Individualize dosage according to patient’s requirements and response; titrate dosage to gain maximum therapeutic effect while using the lowest possible effective dosage.e (See Boxed Warning.)

Pediatric Patients


2 mg/kg administered as a single dose.103 104 105 107 108 133 If necessary, increase in increments of 1 or 2 mg/kg every 6–8 hours103 104 105 107 108 to a maximum of 6 mg/kg.103 133 Generally not necessary to exceed individual doses of 4 mg/kg or a dosing frequency of once or twice daily.104 Use minimum effective dosage for maintenance therapy.133

IV or IM

1 mg/kg administered as a single IM or IV injection.103 104 105 106 107 108 150 If necessary for resistant forms of edema, the initial dose may be increased by 1 mg/kg103 104 105 108 no more often than every 2 hours until the desired effect has been obtained or up to a maximum dosage of 6 mg/kg.103 Adequate response usually is obtained with individual parenteral doses of 1 mg/kg.104 105 107 108

Acute Pulmonary Edema
IV or IM

1 mg/kg administered as a single IM or IV injection.103 104 105 106 107 108 150 If necessary for resistant forms of edema, the initial dose may be increased by 1 mg/kg103 104 105 108 no more often than every 2 hours until the desired effect has been obtained or up to a maximum dosage of 6 mg/kg.103 Adequate response generally obtained with 1 mg/kg.104 105 107 108


Initially, 0.5–2 mg/kg given once or twice daily.149 Increase as necessary up to a maximum of 6 mg/kg daily.149



20–80 mg given as a single dose, preferably in the morning.133 e If needed, repeat same dose 6–8 hours later or increase dose by 20- to 40-mg increments and give no sooner than 6–8 hours after last dose until desired diuretic response (including weight loss) is obtained.133 e May titrate carefully up to 600 mg daily in severe cases.133

The effective dose may be given once or twice daily thereafter, or, in some cases, by intermittent administration on 2–4 consecutive days each week.133 e Dosage may be reduced for maintenance therapy.e

IV or IM

20–40 mg given as a single IM or IV injection.150 e If needed, repeat same dose 2 hours later or increase dose by 20-mg increments and give no sooner than every 2 hours until the desired diuretic response is obtained.150 Effective dosages may then be given once or twice daily.150

Acute Pulmonary Edema

40 mg given as a single IV injection.150 If needed, an 80-mg dose may be given 1 hour after the initial dose.150


40 mg twice daily.133 If desired BP not attained, consider adding other antihypertensive agents.133

Usual dosage recommended by JNC 7: 10–40 mg twice daily.127 144

Prescribing Limits

Pediatric Patients


Maximum of 6 mg/kg.103 133

IV or IM

Maximum of 6 mg/kg in infants and children; do not exceed 1 mg/kg daily in premature infants.150


Maximum 6 mg/kg daily.149



Maximum of 600 mg daily.133

Special Populations

Renal Impairment

Higher doses may be required for patients with acute or chronic renal failure.e


Higher doses may be required for patients with acute or chronic renal failure.e


Use of ≥3 antihypertensive agents usually is required to achieve a target BP <130/80 mm Hg.144

Cautions for Furosemide


  • Anuria.133

  • Known hypersensitivity to furosemide or any ingredient in the formulation.133



Hepatic Effects

Sudden alterations of electrolyte balance in patients with cirrhosis may precipitate hepatic coma; use with caution in patients with hepatic cirrhosis and ascites.133

Do not initiate therapy in patients with hepatic coma or electrolyte depletion until the basic condition is improved.133 Therapy in such patients is best initiated in the hospital with careful monitoring of clinical status and electrolyte balance.133

Renal Effects

If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, discontinue the drug.133 150

Sensitivity Reactions


Anaphylaxis (e.g., urticaria, angioedema, hypotension) within 5 minutes after IV administration reported.102

Systemic Lupus Erythematosus

Possible exacerbation or activation of systemic lupus erythematosus.133 150

Sulfonamide Sensitivity

Patients sensitive to sulfonamides may show allergic reactions to furosemide.e


Photosensitivity may occur.133

Major Toxicities


Risk of tinnitus, reversible or permanent hearing impairment increased following IV or IM administration, especially at high dosages,133 e after too-rapid administration,133 in patients with severely impaired renal function, and/or in patients receiving other ototoxic drugs (e.g., aminoglycosides).133 e (See Specific Drugs under Interactions.)

If high-dose IV therapy is indicated, administer by slow IV infusion (e.g., at a rate not exceeding 4 mg/minute in adults).133 150

General Precautions

Fluid, Electrolyte, and Cardiovascular Effects

Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients.133 (See Boxed Warning.)

Risk of orthostatic hypotension, especially with brisk diuresis.133 150 151 May be aggravated by concomitant use with alcohol, barbiturates, or narcotics.133 151 e

Risk of hypokalemia, especially with brisk diuresis, inadequate oral electrolyte intake, when cirrhosis is present, or during concomitant use of corticosteroids or ACTH.133 150 Concomitant therapy with digitalis may exaggerate metabolic effects of hypokalemia, especially myocardial effects.133 150

Observe carefully for manifestations of fluid and electrolyte depletion (e.g., dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, nausea, vomiting).133

Endocrine Effects

Possible increased blood glucose and alterations in glucose tolerance tests (with abnormalities of the fasting and 2-hour postprandial sugar); precipitation of diabetes mellitus rarely reported.133 150 Monitor urine and blood glucose concentrations periodically in patients with diabetes and those suspected of latent diabetes.e

Possible hyperuricemia and precipitation of gout;133 150 use with caution in patients with a history of gout or elevated serum uric acid concentrations.e

Patient Monitoring

Monitor regularly for the possible occurrence of blood dyscrasias, liver or kidney damage, or other idiosyncratic reactions.133 150

Serum electrolytes (particularly potassium), CO2, creatinine and BUN should be determined frequently during the first few months of therapy and periodically thereafter.133 150

Elective Surgery

Discontinue therapy 1 week (oral furosemide) or 2 days (parenteral furosemide) before elective surgery.e

Specific Populations


Category C.133


Distributed into milk.133 Use with caution.133

Pediatric Use

Risk of persistent patent ductus arteriosus (PDA) may be increased in premature neonates with respiratory distress syndrome (RDS) who receive furosemide during the first weeks of life.103 e

Do not exceed dosage of 1 mg/kg per 24 hours in premature neonates with <31 weeks’ postconception age (gestational age at birth plus postnatal age); risk of potentially toxic furosemide plasma concentrations with higher dosages.150

Renal calcification reported in severely premature infants treated with IV furosemide for edema due to PDA and hyaline membrane disease; concomitant chlorothiazide therapy may decrease hypercalciuria and dissolve some calculi.150

Hearing loss reported in neonates; possibly secondary to renal immaturity.103 125 126 150

Oral solutions contain sorbitol; high dosages may cause diarrhea in children.e

Hepatic Impairment

Use with caution.133 e

Renal Impairment

Use with caution.133 e

Common Adverse Effects

Orthostatic hypotension, dizziness, electrolyte imbalance (hyponatremia, hypokalemia, hypochloremia) tinnitus, photosensitivity.133 e

Interactions for Furosemide

Specific Drugs





May aggravate orthostatic hypotension133 151 e

Anticonvulsant agents (e.g., phenytoin sodium, phenobarbital)

Possible reduced diuretic effecte

Antidiabetic agents (e.g., insulin, oral agents)

Possible antagonism of hypoglycemic effect as result of hypokalemia133

Observe for possible decreased diabetic control; correct potassium deficit and/or adjust dosage of antidiabetic agente

Antihypertensive agents

Additive antihypertensive effect; orthostatic hypotension may occur133

Reduce dosage of both drugse

Concomitant therapy generally used to therapeutic advantagee


May aggravate orthostatic hypotension133 151 e

Cardiac glycoside (e.g., digoxin)

Possible electrolyte disturbances (e.g., hypokalemia, hypomagnesemia), increased risk of digitalis toxicity, and/or fatal cardiac arrhythmias e

Monitor electrolytes; correct hypokalemia e

Chloral hydrate

Possible reaction characterized by diaphoresis, flushes, hypertension, and uneasiness in patients with acute MI and CHFe

Consider alternate hypnotic drug (e.g., a benzodiazepine) in patients who require IV furosemidee

Diuretics, loop (e.g., bumetanide, ethacrynic acid, torsemide)

Share similar diuretic mechanisms e

No therapeutic rationale for concomitant usee

Diuretics, potassium- sparing (e.g., amiloride, spironolactone, triamterene)

Possible reduction in potassium loss 133

May be used to therapeutic advantage133

Diuretics, thiazides

Additive diuretic effecte

Use reduced dosage of furosemide when added to existing diuretic regimene

Drugs that cause potassium loss (e.g., corticosteroids, corticotropin, amphotericin B)

Additive hypokalemic effects133 e

Monitor electrolytes; correct hypokalemia 133 e


Possible decreased diuretic and natriuretic effect133

Monitor closely to determine if desired diuretic and/or hypotensive effect is obtained133


Reduced renal clearance of lithium and increased risk of lithium toxicity 133

Avoid concomitant use;133 e if concomitant therapy is necessary, monitor for lithium toxicitye


May aggravate orthostatic hypotension133 151 e

Neuromuscular blocking agents, nondepolarizing (e.g., atracurium besylate, tubocurarine chloride)

Potential for prolonged neuromuscular blockadee


Decreased arterial responsive to norepinephrine133

Norepinephrine may still be used effectively133

Ototoxic drugs (e.g., aminoglycoside antibiotics)

Possible additive ototoxic effect, especially in patients with impaired renal function133

Avoid concomitant use except in life-threatening situations133

Salicylates (e.g., aspirin, NSAIAs)

Possible transient reductions in Clcr in patient with chronic renal insufficiencye

Possible weight gain and increased Scr, serum potassium concentrations, and BUN (NSAIAs)133

Monitor for toxicity133


May potentiate action of succinylcholine133


Possible reduced natriuretic and antihypertensive effects133

Do not administer simultaneously; separate administration by ≥2 hours133

Observe closely for desired diuretic and/or antihypertensive effect133

Uricosuric drugs (probenecid, sulfinpyrazone)

Possible antagonism of uricosuric effectse

Monitor serum uric acid concentrationse

Furosemide Pharmacokinetics



Mean oral bioavailability of furosemide from commercially available tablets and oral solution is 64% and 60%, respectively.133

Commercially available tablets and oral solution are bioequivalent.133


Following oral administration, onset of diuresis occurs within 30 minutes to 1 hour; maximal effect after 1–2 hours.133 e

Following IV administration, diuresis occurs within 5 minutes and peaks within 20–60 minutes.150 e

Onset of diuresis after IM administration occurs somewhat later than after IV administration.150

Maximum hypotensive effect may not be apparent until after several days of therapy.e


Diuretic effect persists 6–8 hours following oral administration and approximately 2 hours following IV administration.133 150 e


Food does not appear to affect diuretic effect.e

Special Populations

In patients with severely impaired renal function, the diuretic response may be prolonged.e



Crosses the placenta and is distributed into milk.e

Plasma Protein Binding

Approximately 95% bound to plasma proteins (mainly albumin) in both normal and azotemic patients.133 e



Metabolized in the liver to the defurfurylated derivative, 4-chloro-5-sulfamoylanthranilic acid.e

Elimination Route

Rapidly excreted in urine by glomerular filtration and by secretion from the proximal tubule.e

Approximately 50% of an oral dose and 80% of an IV or IM dose are excreted in urine within 24 hours; 69–97% of these amounts is excreted in the first 4 hours.150 e The remainder of the drug is eliminated by nonrenal mechanisms including degradation in the liver and excretion of unchanged drug in the feces.e


Biphasic;e terminal half-life is approximately 2 hours.133

Special Populations

Hepatic or renal impairment prolongs the elimination half-life of the drug.e

In patients with marked renal impairment without liver disease, nonrenal clearance is increased to the extent that up to 98% of the drug is cleared within 24 hours.e

Not removed by hemodialysis.133




Solution or Tablets

Tight, light resistant containers at 15–30°C.133 151



15–30°C; protect from light.150 Discard unused portion.150


For information on systemic interactions resulting from concomitant use, see Interactions.


Do not mix with strongly acidic solutions (i.e., pH < 5.5), such as those containing ascorbic acid, amrinone, ciprofloxacin, labetalol, tetracycline, milrinone, epinephrine, or norepinephrine, because furosemide may be precipitated.150 e

Solution Compatibilitya


Alcohol 5% and dextrose 5%

Amino acids 4.25%, dextrose 25%

Dextrose 5% in Ringer’s injection, lactated

Dextrose 5% in sodium chloride 0.9%

Dextrose 5, 10, or 20% in water

Invert sugar 10% in Electrolyte #1

Mannitol 20%

Ringer’s injection, lactated

Sodium chloride 0.9%

Sodium lactate (1/6) M


Fructose 10% in water

Invert sugar 10% in Electrolyte #2

Drug Compatibility
Admixture Compatibilitya


Amikacin sulfate


Ampicillin sodium

Atropine sulfate


Calcium gluconate

Cefuroxime sodium

Cimetidine HCl

Dexamethasone sodium phosphate

Diamorphine HCl


Epinephrine HCl

Heparin sodium

Hydrocortisone sodium succinate

Isosorbide dinitrate

Kanamycin sulfate

Lidocaine HCl

Midazolam HCl


Morphine sulfate


Penicillin G

Potassium chloride

Ranitidine HCl

Scopolamine butylbromide

Sodium bicarbonate



Tobramycin sulfate


Buprenorphine HCl

Chlorpromazine HCl


Dobutamine HCl

Erythromycin lactobionate

Isoproterenol HCl

Meperidine HCl

Metoclopramide HCl


Prochlorperazine edisylate

Promethazine HCl


Amiodarone HCl

Gentamicin sulfate

Hydrocortisone sodium succinate

Verapamil HCl

Y-Site Compatibilitya


Allopurinol sodium


Amikacin sulfate

Amphotericin B cholesteryl sulfate complex



Bleomycin sulfate

Cefepime HCl






Dexmedetomidine HCl


Doxorubicin HCl liposome injection

Epinephrine HCl

Etoposide phosphate

Fentanyl citrate

Fludarabine phosphate


Foscarnet sodium

Granisetron HCl

Heparin sodium

Hetastarch in lactated electrolyte injection (Hextend)

Hydrocortisone sodium succinate

Hydromorphone HCl

Indomethacin sodium trihydrate

Kanamycin sulfate

Leucovorin calcium



Melphalan HCl


Methotrexate sodium



Norepinephrine bitartrate


Piperacillin sodium–tazobactam sodium

Potassium chloride


Ranitidine HCl

Remifentanil HCl


Sodium nitroprusside


Tirofiban HCl




Tobramycin sulfate

Vitamin B complex with C




Chlorpromazine HCl



Diltiazem HCl


Esmolol HCl

Fenoldopam mesylate




Gemcitabine HCl

Gentamicin sulfate

Hydralazine HCl

Idarubicin HCl


Metoclopramide HCl

Midazolam HCl

Milrinone lactate

Nicardipine HCl

Ondansetron HCl

Quinidine gluconate

Thiopental sodium

Vecuronium bromide

Vinblastine sulfate

Vincristine sulfate

Vinorelbine tartrate


Amiodarone HCl

Dobutamine HCl

Dopamine HCl

Doxorubicin HCl


Labetalol HCl

Meperidine HCl

Morphine sulfate


  • Inhibits primarily the absorption of sodium and chloride not only in the proximal and distal tubules but also in the ascending limb of the loop of Henle.133 e Does not inhibit carbonic anhydrase and is not an aldosterone antagonist.e

  • Mechanism of hypotensive effect not definitively determined but presumed to result from decreased plasma volume.e

  • Induces greater diuresis and electrolyte loss than with thiazides or most other diuretics except ethacrynic acid.e

  • Possesses some renal vasodilator effect; renal vascular resistance decreases and renal blood flow increases following administration.e

Advice to Patients

  • Risks associated with excessive fluid loss or electrolyte imbalance.133

  • Potential for postural hypotension; importance of rising slowly from a seated position.133

  • Importance of discussing dietary measures and supplementation to prevent or correct hypokalemia.133

  • Importance of informing patients with diabetes mellitus that blood glucose and urine glucose concentrations may increase.133 e

  • Importance of informing patients of possible photosensitivity.133 e

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs (e.g., appetite suppressants, cold remedies) as well as any concomitant illnesses.133 e

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.133 e

  • Importance of informing patients of other important precautionary information.133 e (See Cautions.)


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name



Dosage Forms


Brand Names




40 mg/5 mL*

Furosemide Solution (with alcohol 0.2% and sorbitol)


10 mg/mL*

Furosemide Solution

Morton Grove, Roxane


20 mg*

Furosemide Tablets

IVAX, Mylan, Qualitest, Roxane, Sandoz, UDL



40 mg*

Furosemide Tablets

IVAX, Mylan, Qualitest, Roxane, Sandoz, UDL

Lasix (scored)


80 mg*

Furosemide Tablets

Mylan, Qualitest, Roxane, Sandoz, UDL





10 mg/mL*

Furosemide Injection

American Pharmaceutical Partners, American Regent, Hospira, IMS

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Furosemide 10MG/ML Solution (MORTON GROVE PHARMACEUTICALS): 120/$15.99 or 360/$35.97

Furosemide 10MG/ML Solution (ROXANE): 60/$17.99 or 120/$25.98

Furosemide 20MG Tablets (SANDOZ): 100/$13.99 or 200/$18.97

Furosemide 40MG Tablets (SANDOZ): 100/$13.99 or 200/$19.96

Furosemide 80MG Tablets (SANDOZ): 30/$12.99 or 60/$15.98

Lasix 20MG Tablets (SANOFI-AVENTIS U.S.): 30/$24.25 or 90/$45.92

Lasix 40MG Tablets (SANOFI-AVENTIS U.S.): 30/$25.99 or 90/$54.91

Lasix 80MG Tablets (SANOFI-AVENTIS U.S.): 30/$35.99 or 90/$85.97


This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions April 2010. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.


Only references cited for selected revisions after 1984 are available electronically.

100. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1984; 144:1045-57. [IDIS 184763] [PubMed 6143542]

101. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1980; 140:1280-5. [IDIS 375724] [PubMed 6775608]

102. Hansbrough JR, Wedner HJ, Chaplin DD et al. Anaphylaxis to intravenous furosemide. J Allergy Clin Immunol. 1987; 80:538-41. [IDIS 235418] [PubMed 3668117]

103. Hoechst-Roussel. Lasix (furosemide) injection, oral solution, and tablets prescribing information (dated 1994 Oct). In: Physicians’ desk reference. 50th ed. Montvale NJ: Medical Economics Company Inc; 1996:1240-2.

104. Engle MA, Lewy JE, Lewy PR et al. The use of furosemide in the treatment of edema in infants and children. Pediatrics. 1978; 62:811-8. [IDIS 118470] [PubMed 724325]

105. Baliga R, Lewy JE. Pathogenesis and treatment of edema. Pediatr Clin North Am. 1987; 34:639-48. [PubMed 3588044]

106. Repetto HA, Lewy JE, Braudo JL et al. The renal functional response to furosemide in children with acute glomerulonephritis. J Pediatr. 1972; 80:660-6. [PubMed 5015080]

107. Lewy JE. Diuretics in infancy. Controversies Nephrol. 1981; 27:33-44.

108. Lewy JE, Moel DI. Pathogenesis and management of edema in the newborn. Clin Perinatol. 1975; 2:117-23. [PubMed 1102212]

109. 1988 Joint National Committee. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988; 148:1023-38. [IDIS 242588] [PubMed 3365073]

110. Lardinois CK, Neuman SL. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med. 1988; 148:1280-8. [IDIS 242671] [PubMed 2897834]

111. Holland OB, Pool PE. Metabolic changes with antihypertensive therapy of the salt-sensitive patient. Am J Cardiol. 1988; 61:53-9H.

112. Weinberger MH. Diuretics and their side effects: dilemma in the treatment of hypertension. Hypertension. 1988; 11(Suppl II):II-16-20.

113. Ames R. Effects of diuretic drugs on the lipid profile. Drugs. 1988; 36(Suppl 2):33-40. [IDIS 248276] [PubMed 3063504]

114. Lasser NL, Grandits G, Caggiula AW et al. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med. 1984; 76(Suppl 2A):52-66. [IDIS 182290] [PubMed 6367451]

115. Bloomgarden ZT, Ginsberg-Fellner F, Rayfield EJ et al. Elevated hemoglobin A1c and low-density lipoprotein cholesterol levels in thiazide-treated diabetic patients. Am J Med. 1984; 77:823-7. [IDIS 192589] [PubMed 6496535]

116. Gluck Z, Baumgartner G, Weidmann P et al. Increased ratio between serum beta- and alpha-lipoproteins during diuretic therapy: an adverse effect? Clin Sci Mol Med Suppl. 1978; 4:325-8s.

117. Ames RP, Hill P. Antihypertensive therapy and the risk of coronary heart disease. J Cardiovasc Pharmacol. 1982; 4(Suppl 2):S206-12. [PubMed 6177958]

118. Ames RP, Hill P. Improvement of glucose tolerance and lowering of glycohemoglobin and serum lipid concentrations after discontinuance of antihypertensive drug treatment. Circulation. 1982; 65:899-904. [IDIS 150695] [PubMed 7042109]

119. Perola P, Lehto H, Lammintausta R et al. Metabolic effects of furosemide and the combination of furosemide and triamterene. Curr Ther Res. 1985; 37:545-53.

120. Weinberger MH. Antihypertensive therapy and lipids: evidence, mechanisms, and implications. Arch Intern Med. 1985; 145:1102-5. [IDIS 200606] [PubMed 2860883]

121. Gerlag PGG, van Meijel JJM. High-dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med. 1988; 148:286-91. [IDIS 238227] [PubMed 3341836]

122. Weidmann P, Gerber A. Effects of treatment with diuretics on serum proteins. J Cardiovasc Pharmacol. 1984; 6(Suppl 1):S260-8. [PubMed 6204152]

123. Weidmann P, Gerber A, Mordasini R. Effects of antihypertensive therapy on serum lipoproteins. Hypertension. 1983; 5(5 part 2):III-120-3. [PubMed 6138309]

124. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993; 153:154-83. [IDIS 309043] [PubMed 8422206]

125. Tuck S, Morselli P, Broquaire M et al. Plasma and urinary kinetics of furosemide in newborn infants. J Pediatr. 1983; 103:481-5. [IDIS 175138] [PubMed 6886918]

126. Mirochnick MH, Miceli JJ, Kramer PA et al. Furosemide pharmacokinetics in very low birth weight infants. J Pediatr. 1988; 112:653-7. [IDIS 250936] [PubMed 3351693]

127. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health. (NIH publication No. 98-4080.)

128. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80. [IDIS 365188] [PubMed 8622249]

129. Psaty BM, Smith NL, Siscovich DS et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA. 1997; 277:739-45. [IDIS 380501] [PubMed 9042847]

130. Whelton PK, Appel LJ, Espeland MA et al. for the TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998; 279:839-46. [PubMed 9515998]

131. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: approaches to the prevention of heart failure. Am J Cardiol. 1999; 83:9-38A.

132. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA. 1988; 259:539-44. [IDIS 237362] [PubMed 2447297]

133. Aventis Pharmaceuticals. Lasix (furosemide) tablets prescribing information. Bridgewater, NJ; 2004 Jan.

134. Sherman LG, Liang CS, Baumgardner S et al. Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clin Pharmacol Ther. 1986; 40:587-94. [IDIS 224725] [PubMed 3533372]

135. Patterson JH, Adams KF Jr, Applefeld MM et al. Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Pharmacotherapy. 1994; 14:514-21. [IDIS 336083] [PubMed 7997385]

136. Wilson JR, Reichek N, Dunkman WB et al. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med. 1981;70:234-9.

137. Parker JO. The effects of oral ibopamine in patients with mild heart failure—a double blind placebo controlled comparison to furosemide. Int J Cardiol. 1993; 40:221-7. [PubMed 8225657]

138. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. [PubMed 10818056]

139. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. [PubMed 10818055]

140. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. [IDIS 452007] [PubMed 10977801]

141. Associated Press (American Diabetes Association). Diabetics urged: drop blood pressure. Chicago, IL; 2000 Aug 29. Press Release from web site.

142. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-42. [IDIS 490723] [PubMed 12479770]

143. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. [IDIS 490721] [PubMed 12479763]

144. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VII) Express. Bethesda, MD: May 14 2003. From NIH website. (Also published in JAMA. 2003; 289.

145. Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension. 2003; 21:1011-53.

146. The Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. 1999 guidelines for the management of hypertension. J Hypertension. 1999; 17:392-403.

147. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. J Am Coll Cardiol. 2001;38:2101-2113.

148. The Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. 1999 guidelines for the management of hypertension. J Hypertension. 1999; 17:392-403.

149. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114(Suppl 2):555-76. [PubMed 15286277]

150. American Pharmaceutical Partners, Inc. Furosemide Injection, USP prescribing information. Schaumburg, IL; 2002 Apr.

151. Roxane Laboratories, Inc. Furosemide tablets and oral solution prescribing information. Columbus, OH; 2003 Aug.

a. Trissel LA. Handbook on injectable drugs. 12th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2003:175-80.

e. AHFS Drug Information 2004. McEvoy GK, ed. Furosemide. American Society of Health-System Pharmacists; 2004: 2260-4.